secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001764013-25-000078
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant appoints new CEO/CFO, expands IMVT-1402 into Sjögren's and CLE
-------------------------------------------------------------------------

- CEO Peter Salzmann retired; Eric Venker (Roivant President) appointed CEO, effective April 21.
- CFO Renee Barnett stepped down; Tiago Girao appointed CFO with $481K salary and $6.66M equity award.
- Board changes: George Migausky resigned; Robert Susman and Jacob Bauer appointed as directors.
- IMVT-1402 IND cleared for potential registrational study in Sjögren's disease, start summer 2025.
- Proof-of-concept study in Cutaneous Lupus Erythematosus initiated; cash runway through Graves' readout in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/imvt-20250418.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer